IDEXX Laboratories Inc experienced a price decline of 3.01%, hitting a 20-day low during regular trading. This movement occurs amid broader market strength, with the Nasdaq-100 up 0.32% and the S&P 500 up 0.40%. The stock's drop suggests sector rotation as investors shift their focus away from certain sectors.
The decline in IDEXX's stock price is attributed to sector rotation, as the overall market shows strength while IDEXX faces selling pressure. This indicates that investors are reallocating their investments, potentially moving towards sectors that are currently performing better.
As IDEXX Laboratories Inc continues to navigate this challenging environment, the implications of this sector rotation could affect its future performance. Investors may need to reassess their positions in light of these market dynamics.
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 687.740
Low
750.00
Averages
792.78
High
850.00
Current: 687.740
Low
750.00
Averages
792.78
High
850.00
Barclays
Glen Santangelo
Overweight
initiated
$850
2025-12-08
Reason
Barclays
Glen Santangelo
Price Target
$850
AI Analysis
2025-12-08
initiated
Overweight
Reason
Barclays analyst Glen Santangelo initiated coverage of Idexx Laboratories with an Overweight rating and $850 price target. The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying investor sentiment is improving as companies shift focus to innovation, margin expansion and de-leveraging. The group's pricing headwinds are easing while debt leverage is coming down, the analyst tells investors in a research note. Barclays sees "plenty of opportunity" as the sector "remains in a transition phase."
Piper Sandler
Neutral
maintain
$700 -> $775
2025-11-10
Reason
Piper Sandler
Price Target
$700 -> $775
2025-11-10
maintain
Neutral
Reason
Piper Sandler raised the firm's price target on Idexx Laboratories to $775 from $700 following quarterly results. The firm keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDXX
Unlock Now
BTIG
Buy
maintain
$785 -> $830
2025-11-04
Reason
BTIG
Price Target
$785 -> $830
2025-11-04
maintain
Buy
Reason
BTIG raised the firm's price target on Idexx Laboratories to $830 from $785 and keeps a Buy rating on the shares after its "strong" Q3 earnings beat. The growth was broad based and the quality of the beat was high, the analyst tells investors in a research note.
UBS
Neutral
maintain
$710 -> $750
2025-11-04
Reason
UBS
Price Target
$710 -> $750
2025-11-04
maintain
Neutral
Reason
UBS raised the firm's price target on Idexx Laboratories to $750 from $710 and keeps a Neutral rating on the shares. The macro is showing signs of life, the analyst tells investors in a research note.
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
